Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial

Commentary on: Padeliporfin Vascular-targeted Photodynamic Therapy Versus Active Surveillance in Men With Low-risk Prostate Cancer (CLIN1001 PCM301): An Open-label, Phase 3, Randomized Controlled Trial

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Urology - Volume 104, June 2017, Pages 7-8

James M.B.Ch.B., Werner J. M.D., Peter C. M.D.,